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Immunological and molecular detection of tumor contamination in leukapheresis products from children with disseminated neuroblastoma: implication for evaluation of tumor cell depletion after CD34 selection
Recently Leung et al reported in Bone Marrow Transplant 1 the results of screening for malignant cells in autologous hematopoietic grafts from five patients with metastatic neuroblastoma, and six patients with Ewing's sarcoma family tumors, by means of reverse transcriptase PCR (RT-PCR) and immunocytochemistry. Tumor cell contamination was identified in the vast majority of the cases (Ͼ80%), but the content of contaminating cells could be reduced by 2.5-3.0 logs via an immunomagnetic CD34 selection of the autografts.
The purpose of the present study was to assess the tumor cell content in peripheral blood stem cell (PBSC) harvests from patients with metastatic neuroblastoma before and after CD34 + cell enrichment in order to evaluate the efficacy of this procedure in terms of indirect tumor cell purging. Detection of contaminating neuroblasts was done using a combination of immunofluorescence assay (IFA) and RT-PCR method. A dual-color fluorochrome labelling with anti-neuroblastoma UJ-13-A and anti-panleucocyte CD45 antibodies, and RT-PCR amplification of tyrosine hydroxylase (TH) mRNA, a tissue-specific marker of neuroblasts, were performed in two different laboratories as already described. after CD34 selection ( Table 1 ). The patients (median age 3 years) had stage IV tumors with bone marrow metastases at diagnosis. At the time of harvesting, the patients were in medullary remission, as assessed by cyto-logical examination of 10 bone marrow aspirates and two core biopsies, but most of them had a bone disease detectable on meta-iodobenzylguanidine scans. CD34 + cell selection was performed by an immunoabsorption method (CellPro, Bothell, WA, USA), and achieved a median purity of 73% (range 46-81%) CD34
+ cells. All samples of both unseparated and CD34 selected harvests were found to be negative by immunofluorescence analysis. In contrast, RT-PCR assay revealed the presence of tumor contamination in nine out of 13 (69%) whole leukapheresis products. After CD34
+ cell selection, one of the nine (11%) grafts examined by RT-PCR showed detectable residual contamination.
The data from immunofluorescence and RT-PCR assays and the information on their sensitivity allowed us to estimate the intervals for the total number of malignant cells contained in PBSC harvests before and after CD34 + cell selection, using the approach proposed by Leung et al. 1 The intervals were calculated on the basis of malignant cell concentrations and total mononuclear cell counts, in whole and CD34 selected fractions. The frequency of tumor cells in the harvests was assumed to be between 1 in 10 5 cells and 1 in 10 6 cells if IFA was negative and RT-PCR was positive. In samples showing no detectable tumor cells by both tests, the tumor cell concentration was considered to be between 0 and 1 in 10 6 . For cases 10-13 in which no PCR data were available after selection, results of immunofluorescence analysis suggested that the residual tumor cell concentration in CD34 selected fractions would be between 0 and 1 in 10 5 . Knowing the absolute number of mononuclear cells in Table 1 Tumor cell detection data in unseparated and CD34-selected PBSCs and evaluation of tumor cell depletion following CD34 selection unseparated and CD34 selected fractions, the boundaries of the interval for the total number of contaminating tumor cells have been determined. The tumor cell depletion after CD34 + cell selection was estimated using the midpoint values of obtained intervals for tumor cell content in the grafts, which is the least biased approach. This enabled us to calculate an average log depletion for each case, which varied from 2.08 to 3.36 logs (median 2.58). These results are comparable with those obtained in the study of Leung et al, 1 and suggest that a significant reduction of tumor cells in autologous PBSC harvests may be obtained by CD34 selection procedure. In addition, we found a similar level of tumor depletion of 2.32 log in an experimental system with CD34 selection of PBSCs from a healthy donor, that were artificially contaminated with 0.05% IMR-32 neuroblasts (data not shown).
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Quantitative data concerning tumor cell detection in autologous PBSCs from neuroblastoma patients are essential in order to determine the effectiveness of purging strategies. Although the incidence of neuroblastoma cell contamination in PBSCs, found in the present and in other studies, 1,3,4 using sensitive methods is high, the concentration of contaminating malignant cells is low, from 1 in 10 4 to 1 in 10 6 . This is the reason why quantitative immunocytochemical or immunofluorescence assays may fail to detect the tumor contamination while it can be identified by more sensitive RT-PCR analysis. However, considerable variations in the expression of tissue-specific genes in neuroblastoma cells make it difficult to apply quantitative RT-PCR approaches for evaluation of tumor cell contamination levels. 4 Therefore, immunological and molecular tumor detection methods should be applied in conjunction to obtain approximate values of the total tumor cell content of autologous harvests. This approach may be adequate for practical use and, in particular, for comparison of results obtained by different methods of tumor cell depletion in hematopoietic autografts in poor-risk advanced neuroblastoma. The clinical significance regarding the number of contaminating tumor cells in PBSC harvests in this patient group remains to be investigated in a larger series of follow-up studies. 
